Anebulo Pharmaceuticals (ANEB) Income from Continuing Operations (2020 - 2025)
Anebulo Pharmaceuticals (ANEB) posted quarterly Income from Continuing Operations of 2551939.0 for Q4 2025, up 4.82% year-over-year from 2434663.8 in Q4 2024, and up 29.62% quarter-over-quarter from 3626158.0 in Q3 2025.
Anebulo Pharmaceuticals (ANEB) Income from Continuing Operations (2020 - 2025) Analysis & Trends
Anebulo Pharmaceuticals (ANEB) has reported Income from Continuing Operations for 6 consecutive years, with 2551939.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Income from Continuing Operations rose 4.82% year-over-year to 2551939.0; the TTM figure through Dec 2025 stood at 10457070.0 (down 22.81% YoY), while the FY2025 annual figure was 9365568.0, down 13.39% from the prior year.
- Income from Continuing Operations rose to 2551939.0 in Q4 2025 per ANEB's latest filing, from 3626158.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 555832.0 in Q1 2021 and bottomed at 7180300.0 in Q2 2023.
- Historically, Income from Continuing Operations has averaged 3019710.65 across 5 years, with a median of 2751691.5 in 2023.
- Annual changes were most pronounced in 2021 — Income from Continuing Operations tumbled 955.55% — and 2024, when it surged 80.52%.
- Anebulo Pharmaceuticals' Income from Continuing Operations stood at 3468591.0 in 2021, then retreated by 13.64% to 3941668.0 in 2022, then increased by 28.4% to 2822299.0 in 2023, then increased by 5.0% to 2681084.0 in 2024, then rose by 4.82% to 2551939.0 in 2025.
- Business Quant data shows ANEB's Income from Continuing Operations at 2551939.0 in Q4 2025, 3626158.0 in Q3 2025, and 2243726.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Anebulo Pharmaceuticals | 16.43 Mn | 16.43 Mn | - | -2.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.55 Mn |
| Sep 30, 2025 | -3.63 Mn |
| Jun 30, 2025 | -2.24 Mn |
| Mar 31, 2025 | -2.04 Mn |
| Dec 31, 2024 | -2.68 Mn |
| Sep 30, 2024 | -2.49 Mn |
| Jun 30, 2024 | -1.40 Mn |
| Mar 31, 2024 | -1.95 Mn |
| Dec 31, 2023 | -2.82 Mn |
| Sep 30, 2023 | -3.05 Mn |
| Jun 30, 2023 | -7.18 Mn |
| Mar 31, 2023 | -3.20 Mn |
| Dec 31, 2022 | -3.94 Mn |
| Sep 30, 2022 | -2.97 Mn |
| Jun 30, 2022 | -4.55 Mn |
| Mar 31, 2022 | -5.65 Mn |
| Dec 31, 2021 | -3.47 Mn |
| Sep 30, 2021 | -1.55 Mn |
| Jun 30, 2021 | -2.47 Mn |
| Mar 31, 2021 | -555,832.00 |